ACIP June 2019 Update

The Advisory Committee on Immunization Practices (ACIP) holds three meetings each year at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia to review scientific data and vote on vaccine recommendations.

Topics at the ACIP June 2019 meeting, held on June 26 and 27, included:

  • 9vHPV Immunogenicity and Safety Trial in Mid-Adult Females
  • Overview of Health Economic Models for HPV Vaccination of Mid-Adults
  • HPV Vaccines Evidence to Recommendations (EtR) Framework
  • HPV Vaccines Work Group Considerations and Proposed Policy Options
  • Considerations for PCV13 use among adults 65 years or older and summary of the Evidence to Recommendations (EtR) Framework Proposed policy options
  • Combination Vaccines – Summary and Relevant Evidence to Recommendation Information
  • Update: Safety Monitoring and Surveillance for Recombinant Zoster Vaccine (RZV)
  • Herpes Zoster Work Group Summary
  • Pertussis Vaccines EtR Framework, Work Group Considerations and Proposed Policy Options
  • Rabies Vaccine
  • 2018-19 U.S. Influenza Activity
  • 2018-19 Influenza Vaccine Effectiveness
  • 2018-19 Influenza Vaccine Safety
  • Influenza Vaccine Proposed Recommendations for 2019-20
  • Proposed Recommendations for Use of Hepatitis A
  • Dengue Epidemiology in the U.S.
  • Dengvaxia Phase III Clinical Trials and Long Term Follow Up
  • Dengue Vaccine Work Group Considerations and Next Steps

If you haven’t been watching the meeting, the slides, videos, and minutes will be available later.

ACIP June 2019 Meeting Votes

And ACIP members voted on a number of issues, including:

Passed.
Passed.
This changes the 2014 ACIP recommendation to give PCV13 to all adults 65 years or older.
A series of votes on DTaP, Hib, IPV, and hepB got Vaxelis, the newly FDA approved hexavalent vaccine, added to the VFC program.

Coming up tomorrow will be votes on flu, hepatitis A, and meningococcal B vaccines.

More on the ACIP June 2019 Meeting

Last Updated on

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.